Effectiveness of Casirivimab–Imdevimab and Sotrovimab During a SARS-CoV-2 Delta Variant Surge
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
JAMA Network Open
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Effectiveness of Casirivimab-Imdevimab and Sotrovimab During a SARS-CoV-2 Delta Variant Surge: A Cohort Study and Randomized Comparative Effectiveness Trial
JAMA Netw Open 2022 Jul 01;5(7)e2220957, DT Huang, EK McCreary, JR Bariola, TE Minnier, RJ Wadas, JA Shovel, D Albin, OC Marroquin, KE Kip, K Collins, M Schmidhofer, MK Wisniewski, DA Nace, C Sullivan, M Axe, R Meyers, A Weissman, W Garrard, OM Peck-Palmer, A Wells, RD Bart, A Yang, LR Berry, S Berry, AM Crawford, A McGlothlin, T Khadem, K Linstrum, SK Montgomery, D Ricketts, JN Kennedy, CJ Pidro, A Nakayama, RL Zapf, PL Kip, G Haidar, GM Snyder, BJ McVerry, DM Yealy, DC Angus, CW SeymourFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.